A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

摘要

The randomized phase II study ARCHER 1042 explored the impact of prophylactic treatment on select dermatologic and gastrointestinal adverse events (AE) of interest and patient-reported outcomes. Doxycycline reduced the incidence of grade a parts per thousand yen2 select dermatologic AEs of interest by 50% (P = 0.016). Both doxycycline and alclometasone reduced the negative impact in patient-reported dermatologic AEs.ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epidermal growth factor receptor (HER) inhibitor, in development for advanced non-small-cell lung cancer (NSCLC).